This market resolves to Yes if the U.S. Food and Drug Administration (FDA) grants approval to elecoglipron for the treatment of obesity by August 15, 2026. Elecoglipron is AstraZeneca's GLP-1 pill, which has shown promise in clinical trials for weight loss in individuals with and without diabetes.